Mycoplasma Pneumoniae Pneumonia
Conditions
Brief summary
To evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with mycoplasma pneumoniae pneumonia, in comparison with placebo.
Interventions
DIETARY_SUPPLEMENTProbiotic
The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, at discharge, d14).
DIETARY_SUPPLEMENTPlacebo
The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, at discharge, d14).
Sponsors
Wecare Probiotics Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Months to 12 Years
Healthy volunteers
No
Inclusion criteria
1. diagnosis of MPP based on typical clinical manifestations (e.g., fever, cough, abnormal pulmonary auscultation), radiographic evidence of pneumonia on chest imaging, and laboratory findings in accordance with current pediatric community-acquired pneumonia guidelines; 2. MP infection was confirmed in nasopharyngeal secretions and serum samples using PCR and ELISA; 3. age between 6 months and 12 years; 4. disease duration less than 2 weeks; 5. written informed consent provided by the guardians.
Exclusion criteria
1. Previous history of wheezing; 2. Cardiovascular disease and congenital tracheal dysplasia; 3. pneumonia induced by other causes; 4. Dysplasia of bronchial and pulmonary tracts; 5. premature infants; 6. Combined with immunosuppressive diseases; 7. Presence of mental illness.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mycoplasma pneumoniae load | 7天 | Mycoplasma pneumoniae load was detected by tNGS |
Countries
China
Outcome results
None listed